Bristol-Myers Squibb Company (BMY) Holdings Cut by TSP Capital Management Group LLC

TSP Capital Management Group LLC lessened its holdings in Bristol-Myers Squibb Company (NYSE:BMY) by 5.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 57,818 shares of the biopharmaceutical company’s stock after selling 3,167 shares during the quarter. Bristol-Myers Squibb accounts for 1.5% of TSP Capital Management Group LLC’s investment portfolio, making the stock its 23rd largest position. TSP Capital Management Group LLC’s holdings in Bristol-Myers Squibb were worth $3,222,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the business. Bbva Compass Bancshares Inc. lifted its position in shares of Bristol-Myers Squibb by 1.5% during the 1st quarter. Bbva Compass Bancshares Inc. now owns 47,772 shares of the biopharmaceutical company’s stock valued at $2,598,000 after buying an additional 711 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its position in shares of Bristol-Myers Squibb by 6.7% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 855,037 shares of the biopharmaceutical company’s stock valued at $47,492,000 after buying an additional 53,474 shares during the last quarter. Grisanti Capital Management LLC lifted its position in shares of Bristol-Myers Squibb by 89.2% during the 1st quarter. Grisanti Capital Management LLC now owns 3,690 shares of the biopharmaceutical company’s stock valued at $201,000 after buying an additional 1,740 shares during the last quarter. Community Bank N.A. lifted its position in shares of Bristol-Myers Squibb by 13.8% during the 1st quarter. Community Bank N.A. now owns 34,930 shares of the biopharmaceutical company’s stock valued at $1,900,000 after buying an additional 4,240 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC lifted its position in shares of Bristol-Myers Squibb by 1.4% during the 1st quarter. Sheaff Brock Investment Advisors LLC now owns 64,999 shares of the biopharmaceutical company’s stock valued at $3,535,000 after buying an additional 910 shares during the last quarter. Hedge funds and other institutional investors own 69.51% of the company’s stock.

In other news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the transaction, the senior vice president now directly owns 46,297 shares in the company, valued at approximately $2,777,820. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.23% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Bristol-Myers Squibb Company (BMY) Holdings Cut by TSP Capital Management Group LLC” was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://sportsperspectives.com/2017/11/15/bristol-myers-squibb-company-bmy-holdings-cut-by-tsp-capital-management-group-llc.html.

Shares of Bristol-Myers Squibb Company (NYSE BMY) opened at $61.25 on Wednesday. Bristol-Myers Squibb Company has a 1-year low of $46.01 and a 1-year high of $66.10. The firm has a market capitalization of $99,822.34, a PE ratio of 20.60, a price-to-earnings-growth ratio of 2.40 and a beta of 1.18. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The business had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.20 billion. During the same period in the previous year, the business earned $0.77 EPS. The business’s revenue was up 6.7% on a year-over-year basis. equities research analysts forecast that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were issued a $0.39 dividend. The ex-dividend date of this dividend was Thursday, October 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.55%. Bristol-Myers Squibb’s payout ratio is currently 61.42%.

BMY has been the topic of a number of recent research reports. Vetr cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $61.66 price target on the stock. in a research report on Tuesday, July 25th. BMO Capital Markets reaffirmed an “underperform” rating and set a $47.00 price target (down previously from $51.00) on shares of Bristol-Myers Squibb in a research report on Wednesday, July 26th. Piper Jaffray Companies set a $60.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Thursday, July 27th. Leerink Swann dropped their price target on Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating on the stock in a research report on Friday, July 28th. Finally, BidaskClub cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. One analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus target price of $64.93.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply